INT78471

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.45
First Reported 1997
Last Reported 2011
Negated 1
Speculated 4
Reported most in Body
Documents 13
Total Number 17
Disease Relevance 12.52
Pain Relevance 3.28

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (CDKN2A) DNA binding (CDKN2A) protein complex (CDKN2A)
cytoplasm (CDKN2A) cytosol (CDKN2A) nucleolus (CDKN2A)
Anatomy Link Frequency
vulva 2
melanocyte 2
podocytes 2
CDKN2A (Homo sapiens)
Pain Link Frequency Relevance Heat
melanocortin 1 receptor 476 97.80 Very High Very High Very High
Chronic pancreatitis 2 85.20 High High
palliative 2 75.04 Quite High
cytokine 11 52.88 Quite High
Inflammation 38 52.48 Quite High
cINOD 500 50.00 Quite Low
aspirin 88 31.96 Quite Low
Pain 8 5.00 Very Low Very Low Very Low
backache 8 5.00 Very Low Very Low Very Low
metalloproteinase 8 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Burns 95 100.00 Very High Very High Very High
Acute Renal Failure 83 100.00 Very High Very High Very High
Skin Cancer 152 99.90 Very High Very High Very High
Aneuploidy 144 99.82 Very High Very High Very High
Tetraploidy 108 99.52 Very High Very High Very High
Metastasis 35 99.12 Very High Very High Very High
Congenital Anomalies 451 99.08 Very High Very High Very High
Melanoma 489 98.36 Very High Very High Very High
Retinoblastoma 9 97.44 Very High Very High Very High
Aging 84 97.36 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
For each baseline endoscopy, samples were characterized for 17p LOH spanning TP53, TP53 mutations, DNA content abnormalities including tetraploidy and aneuploidy, 9p LOH spanning the CDKN2A (p16) locus, CDKN2A promoter methylation, and CDKN2A mutation in one biopsy every 2 cm in the Barrett's segment (average = 3.2, range 1–11 biopsies analyzed per study participant).
Regulation (spanning) of Gene_expression (methylation) of CDKN2A associated with aneuploidy, tetraploidy and congenital anomalies
1) Confidence 0.45 Published 2007 Journal PLoS Medicine Section Body Doc Link PMC1808095 Disease Relevance 0.62 Pain Relevance 0
For each baseline endoscopy, samples were characterized for 17p LOH spanning TP53, TP53 mutations, DNA content abnormalities including tetraploidy and aneuploidy, 9p LOH spanning the CDKN2A (p16) locus, CDKN2A promoter methylation, and CDKN2A mutation in one biopsy every 2 cm in the Barrett's segment (average = 3.2, range 1–11 biopsies analyzed per study participant).
Regulation (spanning) of Gene_expression (mutation) of CDKN2A associated with aneuploidy, tetraploidy and congenital anomalies
2) Confidence 0.45 Published 2007 Journal PLoS Medicine Section Body Doc Link PMC1808095 Disease Relevance 0.62 Pain Relevance 0
For each baseline endoscopy, samples were characterized for 17p LOH spanning TP53, TP53 mutations, DNA content abnormalities including tetraploidy and aneuploidy, 9p LOH spanning the CDKN2A (p16) locus, CDKN2A promoter methylation, and CDKN2A mutation in one biopsy every 2 cm in the Barrett's segment (average = 3.2, range 1–11 biopsies analyzed per study participant).
Regulation (spanning) of Gene_expression (mutation) of CDKN2A associated with aneuploidy, tetraploidy and congenital anomalies
3) Confidence 0.45 Published 2007 Journal PLoS Medicine Section Body Doc Link PMC1808095 Disease Relevance 0.62 Pain Relevance 0
For each baseline endoscopy, samples were characterized for 17p LOH spanning TP53, TP53 mutations, DNA content abnormalities including tetraploidy and aneuploidy, 9p LOH spanning the CDKN2A (p16) locus, CDKN2A promoter methylation, and CDKN2A mutation in one biopsy every 2 cm in the Barrett's segment (average = 3.2, range 1–11 biopsies analyzed per study participant).
Regulation (spanning) of Gene_expression (mutation) of p16 associated with aneuploidy, tetraploidy and congenital anomalies
4) Confidence 0.45 Published 2007 Journal PLoS Medicine Section Body Doc Link PMC1808095 Disease Relevance 0.62 Pain Relevance 0
For each baseline endoscopy, samples were characterized for 17p LOH spanning TP53, TP53 mutations, DNA content abnormalities including tetraploidy and aneuploidy, 9p LOH spanning the CDKN2A (p16) locus, CDKN2A promoter methylation, and CDKN2A mutation in one biopsy every 2 cm in the Barrett's segment (average = 3.2, range 1–11 biopsies analyzed per study participant).
Regulation (spanning) of Gene_expression (methylation) of p16 associated with aneuploidy, tetraploidy and congenital anomalies
5) Confidence 0.45 Published 2007 Journal PLoS Medicine Section Body Doc Link PMC1808095 Disease Relevance 0.62 Pain Relevance 0
For each baseline endoscopy, samples were characterized for 17p LOH spanning TP53, TP53 mutations, DNA content abnormalities including tetraploidy and aneuploidy, 9p LOH spanning the CDKN2A (p16) locus, CDKN2A promoter methylation, and CDKN2A mutation in one biopsy every 2 cm in the Barrett's segment (average = 3.2, range 1–11 biopsies analyzed per study participant).
Regulation (spanning) of Gene_expression (methylation) of CDKN2A associated with aneuploidy, tetraploidy and congenital anomalies
6) Confidence 0.45 Published 2007 Journal PLoS Medicine Section Body Doc Link PMC1808095 Disease Relevance 0.62 Pain Relevance 0
The survival period was shorter and metastasis is more likely in those cases that did not show p16 expression than those that did.
Neg (not) Regulation (show) of Gene_expression (expression) of p16 associated with metastasis
7) Confidence 0.45 Published 1997 Journal Clin. Cancer Res. Section Abstract Doc Link 9815833 Disease Relevance 0.82 Pain Relevance 0.16
In our analysis, the associations of MC1R variants with melanoma risk did not differ statistically significantly depending on whether CDKN2A mutations altered only the p16INK4a protein or both p16INK4a and p14ARF proteins.
Spec (whether) Regulation (altered) of Gene_expression (protein) of p14ARF associated with melanocortin 1 receptor and melanoma
8) Confidence 0.44 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2957428 Disease Relevance 0.54 Pain Relevance 0.98
Western blot analyses to detect the expression of CBX7, p16(INK4a), and ?
Spec (analyses) Regulation (detect) of Gene_expression (expression) of p16
9) Confidence 0.44 Published 2010 Journal J Exp Clin Cancer Res Section Body Doc Link PMC2933612 Disease Relevance 0.44 Pain Relevance 0.15
In our analysis, the associations of MC1R variants with melanoma risk did not differ statistically significantly depending on whether CDKN2A mutations altered only the p16INK4a protein or both p16INK4a and p14ARF proteins.
Spec (whether) Regulation (altered) of Gene_expression (protein) of p16INK4a associated with melanocortin 1 receptor and melanoma
10) Confidence 0.44 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2957428 Disease Relevance 0.54 Pain Relevance 0.97
In our analysis, the associations of MC1R variants with melanoma risk did not differ statistically significantly depending on whether CDKN2A mutations altered only the p16INK4a protein or both p16INK4a and p14ARF proteins.
Spec (whether) Regulation (altered) of Gene_expression (protein) of p16INK4a associated with melanocortin 1 receptor and melanoma
11) Confidence 0.44 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2957428 Disease Relevance 0.54 Pain Relevance 0.97
No expression of p53 and p16INK4A was detected in normal epithelium of the vulva [20].
Regulation (detected) of Gene_expression (expression) of p16INK4A in vulva
12) Confidence 0.36 Published 2011 Journal Journal of Skin Cancer Section Body Doc Link PMC3003991 Disease Relevance 1.68 Pain Relevance 0
Also, potential new leads to mechanisms explaining the biological activity of curcumin were identified, for example the effect on tubulin genes and differential expression of p16(INK4)/TP53/RB1.
Regulation (effect) of Gene_expression (expression) of p16
13) Confidence 0.32 Published 2004 Journal J Carcinog Section Body Doc Link PMC421747 Disease Relevance 0.32 Pain Relevance 0
Also, potential new leads to mechanisms explaining the biological activity of curcumin were identified, for example the effect on tubulin genes and differential expression of p16(INK4)/TP53/RB1.
Regulation (effect) of Gene_expression (expression) of INK4
14) Confidence 0.32 Published 2004 Journal J Carcinog Section Body Doc Link PMC421747 Disease Relevance 0.32 Pain Relevance 0
Moreover, we demonstrate a correlation between caveolin-1 and p16INK4a gene expression. p16INK4a is a cyclin-dependent kinase inhibitor that prevents retinoblastoma phosphorylation and arrests the cell cycle in the G0/G1 phase prior to entry into the synthesis phase [53,54].
Regulation (correlation) of Gene_expression (expression) of p16INK4a associated with retinoblastoma
15) Confidence 0.28 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2575636 Disease Relevance 0.92 Pain Relevance 0.05
Ha et al., recently used a mouse model to demonstrate that p14ARF but not p53, suppressed early melanomagenesis and operated independent of p53 to induce melanocyte senescence.[57] This added benefit of p14ARF loss may help explain why CDKN2A, as opposed to p53, is preferentially abrogated in melanoma.[4] CDKN2A expression changes were identified in the vast majority of melanomas through mutation, deletion or promoter hypermethylation of CDKN2A gene.[2] CDKN2A harbors mutations in melanoma at dipyrimidine sites but many of these genetic alterations are not UVB signature mutations.[13] An ongoing trial is aimed to identify gene mutations in patients with melanoma and in families with a history of hereditary melanoma and monitors for CDKN2A mutations.[58] Restoring function of a lost or defective gene in cancer has generally proven to be more difficult than blocking a hyperfunctional gene; thus it is not surprising that most efforts in targeted melanoma therapy have focused on suppression of oncogene signaling rather than TSG restoration.
Regulation (changes) of Gene_expression (expression) of CDKN2A in melanocyte associated with aging, cancer, melanoma and skin cancer
16) Confidence 0.25 Published 2010 Journal Journal of Carcinogenesis Section Body Doc Link PMC2862505 Disease Relevance 0.87 Pain Relevance 0
Burns septic ARF group plasma altered polarity, cytoskeleton distribution, permeability and nephrin expression in podocytes
Regulation (Burns) of Gene_expression (expression) of ARF in podocytes associated with acute renal failure and burns
17) Confidence 0.16 Published 2008 Journal Crit Care Section Body Doc Link PMC2447585 Disease Relevance 1.84 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox